Piper Sandler lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 following quarterly results. The firm keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $73 from $70 at Scotiabank
- Exact Sciences Corp Earnings Call Highlights Growth
- Exact Sciences price target lowered to $65 from $75 at BTIG
- Positive Growth Outlook for Exact Sciences Driven by Cologuard Momentum and New Product Launches
- Promising Growth and Strategic Innovation Drive Buy Rating on Exact Sciences